KPTI - Karyopharm Therapeutics Q3 2021 Earnings Preview
Karyopharm Therapeutics (NASDAQ:KPTI) is scheduled to announce Q3 earnings results on Wednesday, November 3rd, before market open. The consensus EPS Estimate is -$0.68 and the consensus Revenue Estimate is $26.29M (+23.3% Y/Y). In September, Seeking Alpha contributor Biologics believes that Karyopharm’s "current valuation along with its upside potential will eventually bring in some buyers at these levels and hopefully inject some bullish sentiment around the ticker". Over the last 3 months, EPS estimates have seen 2 upward revisions and 5 downward. Revenue estimates have seen 2 upward revisions and 5 downward. The company's shares have fallen more than 63% year to date.
For further details see:
Karyopharm Therapeutics Q3 2021 Earnings Preview